Lorena Raquel Lerner, Chief Science Officer at Keros Therapeutics ($KROS), made one open market sale of company shares in the last year, totaling $63,324. Her most recent sale occurred on February 18, 2026. This ranks her 10,119th among 11,678 insiders by sales value, well below the average of $8.6 million across about 6.4 transactions per insider. Lerner reported no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | Keros Therapeutics, Inc. | $KROS | Lerner Lorena Raquel | Chief Scientific Officer | A | Employee Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 41,202,371 | 9999.99% | 0.18% |
| Feb. 18, 2026 | Keros Therapeutics, Inc. | $KROS | Lerner Lorena Raquel | Chief Science Officer | S | Common Stock | 3873 | $16.35 | 31,127.0000 | 41,202,371 | 11.07% | 0.01% |